The application for Orphan Drug Designation for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia was submitted on Oct. 22nd and the FDA granted it on Feb 10th, so just under 4 months later.

They submitted for the ODD and the Pediatric Rare Disease Designation for ESS to treat GCMN on Dec. 29th, so we could get a response anytime now.

The other one I missed was they also submitted for an ODD and the RPDD. Designation for MANF in treatment of Retinitis Pigmentosa on Feb 5th. That would make 2 Rare Ped. Disease Designations.

If we get some good news, I think the stock could jump quite a bit since the toxics have let up on the selling. If the stock would go back to 20-30 cents it would help significantly- The R/S wouldn't need to be as large and the toxics wouldn't need to convert anywhere near as many shares. The stock tanked because of dilution, but mostly because of the potential future dilution that fortunately has not taken place yet.

Conversely, if the price goes up, there is less dilution which in turn helps the price go up and stay up that much more. If we get some good news soon, it could be a huge turning point for the company.